The SEMG refers to the Ministry requested proposals and extends its document also to all the ministries.

-Seven are the specific proposals that he wanted to highlight for health officials the Spanish society general physicians and family (SEMG), that among the factors which stand out as important in the introduction to his paper recognizes the dual responsibility of the physician to the health and well-being of the population and the sustainability of the system. Among the proposals, the SEMG emphasis in order to ensure the same appearance of his treatment to chronic patients while they require

Spain, 2011-October perseverance in the search for consensus for all decisions, assurance of uniform equity of benefits in all Spain and maintenance of the separation of roles between health professionals related to the drug. These are the three keys that the Spanish society of General physicians and family (SEMG) wanted to make clear in the introduction of the document of proposals for further normative development of the Royal Decree 9/2011 from August 19, of measures for the improvement of the quality and consistency of the national health systemand contribution to fiscal consolidation and elevation of the maximum amount of the guarantees of the State by 2011.

A document in which they raised seven specific proposals and that according to the SEMG did reach both the Ministry and officials of the ministries of the autonomous communities, given that, as reflected in the document, our health administrations should ensure that citizens have enforceable and benefits available at each regional health serviceregardless of any other consideration of political or demographic type ”; Besides being desirable ”, point, that any regulation of the pharmaceutical provision carries the highest level of uniformity to not generate any form of discrimination ”. And to achieve this, this scientific society, representative as its name indicates the first level of care doctors, does not hesitate to call upon all parties to persevere on the path of consensus.

New model reference pricing: more flexible mechanism if it is equal to the product and remains the separation of professional roles

Medical professionals are aware that in the performance of our profession in the framework of the national health system must deal with two types of responsibilities: the health and well-being of our patients and our commitment to the sustainability of a health system that depends largely on our therapeutic decisions. All this is based on the up-to-date knowledge and in the choice of drugs of proven safety and efficacy and taking as a reference also costs them ”. And is that the Spanish society of General physicians and family (SEMG) understands that one of the greatest successes of our health care system was to clearly separate the prescription of the dispensation of drugs ”, and not only by commercial involvement, arguing, but especially because the prescriber has substantial information and the best interpretation capacity information concerning the patient ”.

Because the SEMG understands that there is sufficient clinical and ethical reasons to keep that clear separation of roles between health professionals related to the drug ”, and that therefore sufficient corrective mechanisms should be established that do not alter this balance and that none of the actors involved in the manufacture, distribution and dispensing of medications take the power to decide what medicine receives each patient ”. That Yes, ensuring also, as explained, that drugs and health products that choose to join this mechanism should be treated equitably by the health system in facilitating its presence in the heritage of the prescribers ”.

The seven proposals

1 Given the health importance of the measures to be implemented, and in order to ensure the fairness of pharmaceutical submissions in all the national health system, it is essential to absolutely all autonomous communities implement measures these evenly, either by express agreement in the framework of the Interterritorial Council of the national health system, either through the promulgation of a standard enforceable by each one of them.

2. Once it gets underway this modification of the system of reference prices, as all those in a same set conform to that price, it makes no sense from any field of the health administration promote or encourage the prescription of certain medicines to the detriment of others in the same set.

3.-Must ensure that the prescriber is the only one with capacity to choose the medication (either with EFG name added to the manufacturer or trade name) which should be dispensed to the patient.

4. Keep the guarantee stated in article 1, paragraph 6, point 2, that prescription, indication, or authorization of dispensation may be identifying the medication or, where appropriate, health product by its trade name ”.

5. Each patient must ensure the possibility of that over the course of his disease use always the same drug, either through its identification as EFG added to the manufacturer or his trade name.

6.-Ban approaches of the offer direct or indirect of any type of incentive, bonuses, discounts, bonuses or gifts on hand who has direct or indirect interests in the production, manufacture and marketing of medicines to healthcare professionals involved in the cycle of prescription, dispensing and administration of medicines ”contained in article 1, paragraph two, it won’t be a simple forecast if not establish dissuasive and punitive measures real of such behaviors for each of the types of such referral health professionals.

7. In order to limit distortions and the more than probable changes in prescriptions for chronic medications, it is worrying to the provision set out in article 1, section 9, paragraph 3, that the determination of sets and their reference prices, as well as the revision of the already identified sets reference price will be, as soon as possible, when there are requirements in the regulations for the determination of a new set or revision of existing ones, and at least once a year ”. In this sense, it would be desirable to set a minimum period of stability in the price of reference to not promote unnecessary inconveniences in the prescription of long-term drugs for patients with chronic diseases.